login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Drug-eluting balloon revenue to more than double by 2019


Thursday, 31 Oct 2013 10:02

The global sales of drug-eluting balloons across the 10 major markets are expected to witness a significant increase over the coming years, from US$164m in 2012 to US$477m in 2019, at a Compound Annual Growth Rate of 16%, following the product’s launch in the USA and Japanese markets, according to a new report from GlobalData.


The company’s latest report states that by 2019, the USA, UK, France, Germany, Italy, Spain and Japan will account for approximately 70% of the drug-eluting balloon market for coronary artery disease and peripheral arterial disease in the lower extremity. Among the 10 countries covered in the report, the USA is forecast to have the largest share in the drug-eluting balloon market, with 26% by 2019.

The demand for effective therapies targeting indications such as in-stent restenosis and complex lesions, and reducing complications associated with drug-eluting stenting, will be primary drivers behind the market growth, it says in the report. Downstream cost-saving measures are also expected to contribute, along with an increasing prevalence in coronary artery disease and peripheral arterial disease.

Priya Madhavan, GlobalData’s analyst covering cardiovascular devices, says: “The drug-eluting balloon market is a dynamic one, where the technology has the potential to be an alternative therapy option for patients suffering from coronary artery disease and peripheral arterial disease. Drug-eluting balloons can be utilised for select coronary and peripheral indications, including for patients who are not eligible for drug-eluting stents, and we expect this to expand the market over the coming years by targeting challenging patient populations.”

Despite the anticipated level of drug-eluting balloons market growth by 2019, GlobalData also expects a number of barriers to prevent any further increase in revenue.

These include a lack of clinical data and numerous reimbursement issues. The fact that drug-eluting balloons are not reimbursed in the public healthcare system in countries such as France, Brazil and India means that adoption of the technology among these countries is slow. The high-selling price and regulatory challenges surrounding drug-eluting balloons are also proving a hindrance to their take-up, according to the report.

Madhavan continues: “Physicians and regulatory authorities want to see long-term clinical data that demonstrate the superiority of drug-eluting balloon angioplasty when compared with stenting.

“Comparative studies looking at the efficacy of different drug-eluting balloon products are essential for developing therapies that improve patient outcomes, and robust clinical data will assist drug-eluting balloons in receiving approval from the US Food and Drug Association (FDA) and Japanese Pharmaceuticals Medical Devices Agency (PMDA) in order to launch in these markets.”




Add New Comment

Related Items


Most popular


OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression
Wednesday, 18 Jun 2014
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients ... OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression

Medtronic to acquire Covidien for US$42.9 billion in cash and stock
Monday, 16 Jun 2014
The acquistion creates a medical technology and services company with a comprehensive product portfolio and broad global reach. Medtronic to acquire Covidien for US$42.9 billion in cash and stock

FDA advisory panel unanimously recommends approval for Lutonix DCB
Friday, 13 Jun 2014
Lutonix DCB is one step closer to becoming the first US FDA-approved drug-coated balloon for the treatment of patients with femoropopliteal occlusive disease. FDA advisory panel unanimously recommends approval for Lutonix DCB

Features


SPECT can predict cardiovascular mortality in elective aneurysm repair patients
Wednesday, 12 Mar 2014
Kimihiro Komori and Yosuke Inoue analyse the results of a study that concluded that preoperative pharmacologic stress myocardial perfusion SPECT is not only safe, but is also a useful method to ... SPECT can predict cardiovascular mortality in elective aneurysm repair patients

Hybrid techniques for the arch: are they effective and durable?
Monday, 17 Feb 2014
Piergiorgio Cao writes that despite the perioperative mortality risk, the late outcome of endovascular arch repair presents a low rate of aorta-related deaths and reinterventions and acceptable mid-... Hybrid techniques for the arch: are they effective and durable?

Profiles


Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Andrew Holden
Tuesday, 11 Feb 2014
Andrew Holden has been involved in the investigation of several endovascular devices for the ... Andrew Holden

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions